Avalo Therapeutics, Inc. - Common Stock (AVTX)
13.40
+0.40 (3.08%)
NASDAQ · Last Trade: Oct 3rd, 5:28 PM EDT
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · September 29, 2025
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
Via Benzinga · September 29, 2025
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
Via Benzinga · September 29, 2025
Via Benzinga · August 1, 2025
Via Benzinga · May 14, 2025
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target.
Via Benzinga · March 25, 2025
Via Benzinga · March 25, 2025

Via Benzinga · February 28, 2025

Via Benzinga · September 3, 2024

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024

Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions.
Via InvestorPlace · July 24, 2024

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · May 24, 2024

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 13, 2024

Via Benzinga · April 29, 2024

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.
Via Benzinga · April 16, 2024

Via Benzinga · April 9, 2024

Via Benzinga · April 2, 2024

Shares of VirTra, Inc. (NASDAQ: VTSI) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter results.
Via Benzinga · April 2, 2024

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.
Via Benzinga · April 2, 2024

It's time to check out all of the biggest pre-market stock movers worth watching on with the winners and losers of Tuesday!
Via InvestorPlace · April 2, 2024

Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading
Via Benzinga · April 1, 2024

Via Benzinga · April 1, 2024

It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!
Via InvestorPlace · April 1, 2024